Sample deliverable · market-entry report
Build a plant — or enter another way first?
A sample of our Stage 0 for a real Caspian/CIS market. Which market — shown on a call under NDA. Here: the method and the headline conclusion; the specifics (market, niches, partners, prices, regulatory route) come with the full sample.
The question we answered
The starting point was the obvious one: a full plant — an order of magnitude of $26–32M in capital expenditure, to produce locally from day one. The logic made sense: your own plant means control and long-run economics. The question was not 'how to build' but 'whether to, and when' — and the answer diverged from that starting point.
What we found — and why a full plant turned out to be premature
The report is organised by market dimensions, not by 'attractive' hypotheses, and here's what it surfaced:
- The 'obvious' open niches that looked empty going in were, on inspection — a pharmacy-shelf audit set against what's imported versus made locally — mostly already taken: not empty space, but imports it's more profitable to sell than to compete against with a plant.
- Who holds the registrations for foreign manufacturers in this market decides the outcome more than the product itself: one player opened an office without a local registration-holding partner and failed; another entered through a partner and took hold.
- Entering via imports first turned out to be several times cheaper in the early years than building a full plant — while the decision on your own manufacturing can be made later, from confirmed demand rather than a forecast.
- Registration timelines and industrial-park/free-zone incentives were checked separately too — they don't overturn the conclusion: even with a lighter registration track and resident incentives, the early-stage economics still favour imports over construction.
What we recommended instead
First enter the market via imports under a local registration-holding partner (1–2 years), then decide on your own manufacturing once demand is confirmed. Cheaper, faster, and it removes the biggest risk — building the wrong thing.
How we separate fact from hypothesis
In the report we explicitly mark what a primary source confirms versus what needs on-the-ground field verification — we don't pass a guess off as fact. That's exactly why you can make a multi-million decision on such a report, not on optimism.
Full sample — on request
The full deliverable names the market, the specific assessed niches, local partners, real pharmacy prices and the exact regulatory route. We'll walk you through it on a call and scope the same study for your target market.
Request the full sample
Message on Telegram — we'll show the full report and discuss applying the method to your market.
Request the full sample
Message on Telegram — we'll show the full report and discuss applying the method to your market.
Contact: Telegram @pmatveyeu · +375 44 509-04-01 · gxplaunch.com
The specific market, niches and partners are disclosed on a call under NDA. The report is a research-stage artifact; some data is marked as needing field verification.
Source: gxplaunch.com · © 2026 GxP Launch